INTRODUCTION
Behavioral emergencies from acute psychotic disturbances, manic episodes, major depression, bipolar disorder, and substance abuse are responsible for approximately 6% of all emergency department (ED) visits in the United States. 1 Behavioral abnormalities and psychiatric illness can coexist with or be caused by medical disease. [2] [3] [4] [5] Therefore, emergency physicians are frequently required to provide the initial assessment of patients who manifest behavioral abnormalities. Psychiatric consultants request that the emergency physician (1) establish if the patient's symptoms are caused or exacerbated by a medical illness, (2) assess and treat any medical situation that needs acute intervention, and (3) determine if the patient is intoxicated, thereby preventing an accurate psychiatric evaluation. This process has typically been termed ''medical clearance'' but becomes problematic because the term can imply different things to psychiatrists and emergency physicians and because there is no standard process for providing this ''medical clearance.'' [6] [7] [8] [9] Focused medical assessment better describes the process in which a medical etiology for the patient's symptoms is excluded and other illness and/or injury in need of acute care is detected and treated. It is important, for example, to determine in the ED if a cognitive disorder such as dementia or delirium is masquerading as a psychiatric condition (Appendix A). In at least 2 states, organizations of emergency physicians and psychiatrists have together formulated consensus guidelines about what components should be included in the medical assessment of the psychiatric patient in the ED. 10, 11 Focused laboratory and radiologic testing may need to be obtained to ensure the stability of the patient based on their history and physical examination. Psychiatric facilities often have limited resources to further evaluate and treat acute and even chronic illnesses. Thus, the initial ED assessment is often the only medical evaluation the patient will receive. In addition, some laboratory testing, such as toxicologic screens that reveal substance abuse, may be very useful in treatment planning of psychiatric patients even though they may have no impact on medical stabilization. 7, 12 A difficult aspect of the focused medical assessment is clearly determining when a patient is not only medically stable but has the cognitive status suitable for the psychiatric interview, which is especially important, given that substance abuse and acute intoxication often confound the patients' behavioral problems. As such, it is unclear what tests need to be performed along with the history and physical examination to establish that the patient is truly stable in preparation for the psychiatric interview.
This clinical policy uses an evidence-based approach to evaluate the literature and make recommendations regarding the medical evaluation of the psychiatric patient and initial pharmacologic therapy of agitated ED patients requiring treatment. Four questions were generated by the committee that were believed to be important for emergency physicians initially providing care in the ED. Except for question 4, which addresses the agitated patient, this clinical policy assumes that the patients being evaluated have normal vital signs and a noncontributory history and physical examination including normal cognitive function. Specifically excluded are patients with abnormal vital signs, delirium, altered cognition, or abnormal physical examination because they often have medical illness that mandates a symptom-based evaluation that is outside the scope of this guideline. Pediatric patients are also excluded.
Recommendations offered in this policy are not intended to represent the only diagnostic and management options that the emergency physician should consider. The American College of Emergency Physicians (ACEP) clearly recognizes the importance of the individual physician's judgment. Rather, this guideline defines for the physician those strategies for which medical literature exists to provide support for answers to the crucial questions addressed in this policy.
This policy evolved from the 1999 ACEP ''Clinical Policy for the Initial Approach to Patients Presenting with Altered Mental Status.'' including ''psychiatry,'' ''medical clearance,'' ''agitation,'' ''toxicologic screens,'' ''drugs of abuse,'' ''alcohol testing,'' and names of individual drugs. Searches were limited to Englishlanguage sources. Additional articles were reviewed from the bibliography of articles cited. Subcommittee members also supplied articles from their own knowledge base.
The reasons for developing clinical policies in emergency medicine and the approaches used in their development have been enumerated. 14 This policy is a product of the ACEP clinical policy development process and is based on the existing literature; where literature was not available, consensus of emergency and psychiatric physicians was used. Expert review comments were received from individual emergency physicians and psychiatrists and from members of the American Association for Emergency Psychiatry, American Association of Community Psychiatrists, American Psychiatric Association, and Emergency Nurses Association. Their responses were used to further refine and enhance this policy. Clinical policies are scheduled for revision every 3 years; however, interim reviews are conducted when technology or the practice environment changes significantly.
All publications were graded by at least 2 of the subcommittee members into 1 of 3 categories of strength of evidence. Some articles were downgraded on the basis of a standardized formula that considers the size of study population, methodology, validity of conclusions, and potential sources of bias (Appendix B).
During the review process, all articles were given a baseline ''strength of evidence'' by the subcommittee members according to the following criteria:
Strength of evidence Class IdInterventional studies including clinical trials, observational studies including prospective cohort studies, aggregate studies including metaanalyses of randomized clinical trials only.
Strength of evidence Class IIdObservational studies including retrospective cohort studies, case-controlled studies, aggregate studies including other meta-analyses.
Strength of evidence Class IIIdDescriptive cross-sectional studies, observational reports including case series and case reports, consensus studies including published panel consensus by acknowledged groups of experts.
Strength of evidence Class I and II articles were then rated on elements subcommittee members believed were most important in creating a quality work. Class I and II articles with significant flaws or design bias were downgraded on the basis of a set formula (Appendix C). Strength of evidence Class III articles were downgraded if they demonstrated significant flaws or bias. Articles downgraded below strength of evidence Class III were given an ''X'' rating and were not used in formulating recommendations in this policy. An Evidentiary Table was constructed and is included in this policy.
Recommendations regarding patient management were then made according to the following criteria:
Level A recommendations. Generally accepted principles for patient management that reflect a high degree of clinical certainty (ie, based on strength of evidence Class I or overwhelming evidence from strength of evidence Class II studies that directly address all the issues).
Level B recommendations. Recommendations for patient management that may identify a particular strategy or range of management strategies that reflect moderate clinical certainty (ie, based on strength of evidence Class II studies that directly address the issue, decision analysis that directly addresses the issue, or strong consensus of strength of evidence Class III studies).
Level C recommendations. Other strategies for patient management that are based on preliminary, inconclusive, or conflicting evidence, or in the absence of any published literature, based on panel consensus.
There are certain circumstances in which the recommendations stemming from a body of evidence should not be rated as highly as the individual studies on which they are based. Factors such as heterogeneity of results, uncertainty about effect magnitude and consequences, strength of prior beliefs, and publication bias, among others, might lead to such a downgrading of recommendations.
Scope of Application. This guideline is intended for physicians working in hospital-based EDs.
Inclusion Criteria. This guideline is intended for adult patients presenting to the ED with psychiatric symptoms.
Exclusion Criteria. This guideline, with the exception of question 4, is not intended for patients with delirium or abnormal vital signs, altered cognition, or abnormal physical examination. Pediatric patients are also excluded.
CRITICAL QUESTIONS
1. What testing is necessary in order to determine medical stability in alert, cooperative patients with normal vital signs, a noncontributory history and physical examination, and psychiatric symptoms?
In patients with acute behavioral emergencies, emergency physicians are frequently asked to perform detailed screening laboratory and radiologic testing to ''exclude'' medical illnesses that may be causing or contributing to the patient's acute psychiatric symptoms. Patients with suggestive histories or abnormal vital signs and/or physical examination need to have medical illness specifically excluded during their screening evaluation. Gregory et al 9 refer to 4 groups that may be high risk in this regard: the elderly, those with substance abuse, patients without a prior psychiatric history, and those with preexisting or new medical complaints. Anfinson and Kathol 15 identified an additional group at risk: those of lower socioeconomic level. They agree, as do others, that patients presenting with new psychiatric symptoms particularly need careful evaluation in the ED for medical illness. 9, 15, 16 Several class III studies have identified the coexistence of medical illness in patients with psychiatric symptoms by using a routine battery of laboratory testing and recommend using this approach. 2, 3, 16, 17 However, these studies often did not specify what components of the initial history and physical examination were included, who performed the screening, and did not perform all tests on all patients, and the decision about what constituted an ''important'' positive was sometimes arbitrary. Hall et al 2, 3 suggested that a routine battery of laboratory testing be completed on all psychiatric patients being hospitalized, including extensive laboratory testing, urinalysis, ECG, and sleep-deprived electroencephalogram because 46% of their patients had medical illness exacerbating the psychiatric illness, and overall, 80% of the patients had a physical illness requiring treatment. They based their observations on 100 patients admitted directly to a state psychiatric hospital but made no mention of whether a medical screening process was done before that admission. Kolman 17 believed that certain screening tests, ECG, chest radiograph, blood urea nitrogen, and serum B 12, should be obtained in the psychogeriatric population despite the admittedly low yield. Henneman et al 16 studied a group of patients presenting to the ED with new psychiatric complaints. In their series of 100 patients, there was a medical reason for the patients' behavior in 63% of the patients. Their conclusion was that most patients with their first psychiatric presentation have a medical illness as the etiology, and require laboratory testing, as well as head computed tomography and cerebrospinal fluid analysis, in addition to a history and physical examination in their medical clearance evaluation. This study included many patients with delirium, and a large number of their patients had alteration of either vital signs (13% had fever and 37% had tachycardia) or cognitive state (60% were disoriented). Furthermore, their recommended tests were not done for every patient. This study, for the most part, is not relevant to the patient population addressed in this guideline.
On the other hand, a preponderance of reports, also class III, concluded that selective testing was the correct strategy. 12, 15, [18] [19] [20] [21] [22] Dolan and Mushlin 18 demonstrated that extensive, routine laboratory testing is unnecessary. When laboratory testing is done, it should be guided by the patient's clinical evaluation. They also found false positive laboratory results to be 8 times more frequent than true positives (1.8%) in patients with routine testing. Likewise, Ferguson and Dudleston, 19 in their series of patients, discovered a 17% rate of laboratory test abnormalities, but only 2 results were not predicted by the patients' history and physical examination; therefore, they concluded that laboratory testing ought to be done selectively based on clinical need.
White and Barraclough 20 reported abnormal laboratory values in 10.2% of their patients yet determined that most were clinically insignificant. They had 5 cases of thyroid disease in patients with affective disorder. No routine screening tests were suggested by the authors, except for thyroid functions and urinalysis in women. Anfinson and Kathol 15 reviewed the available literature on laboratory testing of psychiatric patients and also concluded that routine laboratory screening was not indicated and that most of the abnormal results obtained were clinically insignificant.
Tintinalli et al 21 analyzed the medical records of 298 ED patients with psychiatric complaints. Although there were major documentation failures noted, only 12 patients (4%) required acute medical treatment within 24 hours of psychiatric admission, and in almost all (83%) patients, the history and physical examination should have identified the problem. Korn et al 22 performed a standard panel of tests in ED patients with psychiatric complaints. They analyzed 80 patients (38% of total) with no self-identified medical complaints but a past psychiatric history. Two of these patients had abnormalities in this standard panel of diagnostic tests: 1 a positive pregnancy test and the other, mild leukocytosis that was considered to be clinically insignificant. The authors concluded that routine laboratory testing in patients with no self-identified medical complaint and a past psychiatric history is unnecessary and patients could be directly referred safely for psychiatric evaluation if they have normal history, physical examination, and vital signs.
Additionally, Olshaker et al 12 retrospectively studied 352 adult ED patients with psychiatric chief complaints. By clinical protocol, all patients were asked about alcohol and recreational drug use. Also by protocol, all patients had laboratory analysis, including CBCs, SMA-7, urine and blood toxicologic screens, and blood alcohol testing. The patients correctly self-reported alcohol use 95% of the time and drug use 91% of the time. Nineteen percent of patients (65 of 352) had an acute medical condition. Of these patients, history identified 94% of them (61 of 65), physical examination 51% (33 of 65), and vital signs 17% (11 of 65). Of the 4 patients not identified by history, 2 had abnormal physical examinations, and the remaining 2 had hypokalemia (2.9 and 3.1 mmol/L). These latter 2 patients were the only ones with abnormalities who had normal history, physical examination, and vital signs. The authors conclude that universal laboratory testing and drug screening is of very low yield.
Future Area of Research: Development of the most efficient tools in the emergency setting for the assessment of cognition and behavioral abnormalities.
Patient management recommendations:
What testing is necessary in order to determine medical stability in alert, cooperative patients with normal vital signs, a noncontributory history and physical examination, and psychiatric symptoms?
Level A recommendations. None specified. Level B recommendations. In adult ED patients with primary psychiatric complaints, diagnostic evaluation should be directed by the history and physical examination. Routine laboratory testing of all patients is of very low yield and need not be performed as part of the ED assessment.
Level C recommendations. None specified.
2. Do the results of a urine drug screen for drugs of abuse affect management in alert, cooperative patients with normal vital signs, a noncontributory history and physical examination, and a psychiatric complaint?
The role of the urine toxicologic screen for drugs of abuse in the evaluation of ED patients with psychiatric complaints is controversial. A survey in 2001 found that almost half of ED physicians required to obtain a urine toxicologic screen for medical clearance thought it was unnecessary. 6 Psychiatrists, on the other hand, may use the results of this screen to help determine the etiology of the patient's symptoms and aid in the patient's disposition and long-term care. Furthermore, the screening results may be required for admission to some facilities. There are no class I or II studies that directly examined how the urine toxicologic screen affects the medical management of a patient with a psychiatric complaint who is alert and cooperative, with a noncontributory history and physical examination, and normal vital signs. There are several class III studies on which recommendations can be based.
Routine toxicologic screening is not supported by the class III studies concerning this issue. A retrospective observational analysis of 352 patients showed that laboratory studies, including urine toxicologic screens, in patients with isolated psychiatric complaints carried a sensitivity of only 20% for organic etiology of their complaint. 12 Therefore, authors suggest that urine toxicologic screens are not indicated routinely. This conclusion is supported by a class III study by Schiller and colleagues 23 examining how the urine drug screen affects disposition of patients from psychiatric emergency services by psychiatrists. In this prospective series, 392 patients were randomized in a blinded fashion to mandatory urine toxicologic screens versus 'usual care,' which may or may not have entailed a urine toxicologic screen. The authors found no difference between the 2 groups for inpatient or outpatient disposition or hospital length of stay and again concluded that the routine use of urine toxicologic screening is not indicated. Unfortunately, this study did not specify the patient's medical status or thoroughly outline 'usual care.' In a class III study by Eisen et al, 24 no justified change in the management plans occurred in 110 patients after the results of a drug of abuse screen became available to the ED clinician. This study did not specify, however, how many of the 110 patients were having a psychiatric evaluation.
Two class III studies advocate obtaining routine urine toxicologic screens, but their data do not seem to support their conclusions in our target population. 3, 16 Hall et al 3 reviewed 100 inpatient psychiatric admissions and reported that 46% had an unrecognized medical problem. However, the urine toxicologic screen identified only 1 of these patients, and its effect on patient management was not discussed. Henneman et al 16 prospectively studied 100 consecutive, alert patients presenting with new psychiatric complaints, although many were noted to have fever, abnormal vital signs, or altered mental status. They found 63 patients with an organic etiology for their symptoms. Thirtyseven percent of these patients were found to have an abnormal alcohol level or urine drugs of abuse screen, of which 29% were believed to be significant. Significance was defined as a result leading to the etiology of the original complaint or resulting in admission. Unfortunately, they did not discuss how these tests changed the patient's management, and imply that a positive urine toxicologic screen result is almost always significant, regardless of whether or not the patient was acutely intoxicated.
In 1999, the Massachusetts College of Emergency Physicians and the Massachusetts Psychiatric Society formed a task force that released consensus recommendations about obtaining toxicologic screens in the ED for drugs of abuse. 11 They concluded that drug screens not required for the evaluation of the medically stable psychiatric patient but requested by the receiving service or facility, if done, should not delay the transfer of the patient.
Do the results of a urine drug screen for drugs of abuse affect management in alert, cooperative patients with normal vital signs, a noncontributory history and physical examination, and a psychiatric complaint?
Level A recommendations. None specified. Level B recommendations. None specified. Level C recommendations.
1. Routine urine toxicologic screens for drugs of abuse in alert, awake, cooperative patients do not affect ED management and need not be performed as part of the ED assessment. 2. Urine toxicologic screens for drugs of abuse obtained in the ED for the use of the receiving psychiatric facility or service should not delay patient evaluation or transfer.
3. Does an elevated alcohol level preclude the initiation of a psychiatric evaluation in alert, cooperative patients with normal vital signs and a noncontributory history and physical examination? Emergency physicians are asked to see intoxicated patients and determine whether they are medically stable for the psychiatric evaluation. Acute intoxication may impair the ability to conduct a valid psychiatric examination. Alcohol acts as a central nervous system depressant, resulting in poor coordination, sluggish reflexes, and emotional lability, and is often a confounding factor in the evaluation, treatment, and disposition of psychiatric patients. Alcohol intoxication can mimic or alter psychiatric symptoms and delay proper patient disposition. 25 Generally, psychiatric facilities will not accept transfers of inebriated patients. Patients impaired by alcohol may not be deemed medically stable. As the blood alcohol concentration decreases, the patient often becomes less impaired, psychiatric symptoms may clear, particularly suicidality, and the need for acute hospitalization is often obviated. [26] [27] [28] There are no evidenced-based data to support a specific blood alcohol concentration at which psychiatric evaluation can accurately commence, nor are there any studies that show that individuals regain adequate decisionmaking capacity when the blood alcohol concentration reaches the legal limit for driving. Cognitive function should be assessed with each patient individually, 29 and this should be the basis for initiating the psychiatric interview rather than a predetermined blood alcohol concentration. Furthermore, there is no evidence in the literature to support the practice of delaying the initiation of psychiatric evaluation to obtain a blood alcohol concentration result if the patient is alert, and has appropriate cognition, normal vital signs, and a noncontributory history and physical examination. Level A recommendations. None specified. Level B recommendations. None specified. Level C recommendations.
1. The patient's cognitive abilities, rather than a specific blood alcohol level, should be the basis on which clinicians begin the psychiatric assessment. 2. Consider using a period of observation to determine if psychiatric symptoms resolve as the episode of intoxication resolves.
4. What is the most effective pharmacologic treatment for the acutely agitated patient in the ED? Agitation characterized by behavioral features such as destructiveness, disorganization, or dysphoria is a frequent finding in ED patients. Such agitated and sometimes violent behavior often poses a serious risk to the patient's health, as well as to the health care providers. Although the focus here will be on the psychopharmacologic management of agitation, clinicians should make every effort to first establish whether the potential for violence can be managed at a verbal or behavioral level before proceeding to management with medications that carry a risk of undesirable side effects.
Benzodiazepines and some antipsychotics have been the pharmacologic agents most used for the control of the agitated patient, and the existing studies have been recently summarized.
30-32 Most were conducted in patients with a known psychiatric diagnosis, so the results cannot necessarily be extrapolated to the undifferentiated agitated patient in the ED. There are also few fixed dose studies directed at determining the appropriate dose of the various agents, and many of the studies permit repeated administration, further clouding the comparability of different agents and doses.
Caution also needs to be taken in caring for patients agitated because of medical illness so that any reversible causes are identified and treated. In addition, agitation may be a result of drug ingestions or poisonings with anticholinergic or sympathomimetic agents. In this scenario, the antipsychotics, both conventional and atypical, and the medications used to manage extrapyramidal symptoms (EPS) can potentially exacerbate agitation because of their anticholinergic side effects. 30 
Benzodiazepines
There are no class I studies using benzodiazepines in patients for acute agitation. There are multiple class II studies demonstrating that benzodiazepines are valuable in reducing agitation and are at least as effective as the conventional antipsychotic haloperidol in control of the agitated patient. demonstrate that benzodiazepine is equivalent to haloperidol in reducing agitation. 37, 38 One class III study reported haloperidol (10 mg) with the addition of promethazine (25 to 50 mg) to have a faster onset of tranquillization than lorazepam (4 mg), but at 4 hours, 96% of subjects in each treatment group were tranquil. The addition of the antihistamine promethazine to control dystonic reactions produced additional sedation. 39 The use of midazolam intramuscular (IM) was recently studied in a randomized, prospective, double-blind class II study by Nobay et al 40 and is the most relevant study of this benzodiazepine in the control of the severely agitated patient. The authors compared IM midazolam (5 mg) to IM lorazepam (2 mg) or IM haloperidol (5 mg). Midazolam had a significantly shorter time to sedation than did lorazepam or haloperidol. The mean time to sedation was 18.3 minutes for midazolam, 28.3 minutes for haloperidol, and 32.2 minutes for lorazepam. The time to arousal (81.9 minutes) in patients given midazolam was also significantly shorter than that of the other therapies.
In addition, several class III studies found midazolam (2.5 to 3 mg IM) to be efficacious in reducing agitation. It produced rapid sedation, within 6 to 8 minutes, in a small series of acutely agitated patients. 41 Midazolam was significantly better than haloperidol in controlling motor agitation in a small study of schizophrenic patients.
42 A large series reported by the TREC Collaborative group 43 found that midazolam (15 mg) was superior to haloperidol (5 mg) plus promethazine (50 mg) in producing rapid sedation at 20-and 40-minute endpoints. At 60 minutes, more than 90% of each group were tranquil or asleep.
A variety of studies has compared the combination of a benzodiazepine with an antipsychotic to either alone. The strongest evidence comes from the large class II ED study by Battaglia et al 34 in which the combination of haloperidol (5 mg) and lorazepam (2 mg) was shown to be superior to lorazepam or haloperidol alone for controlling the patients' acute agitation at 1 hour. Side effects did not differ significantly between the treatment groups, although the incidence of EPS in the haloperidol group was 20%, which is 6 times the rate in lorazepam-treated patients. Level III studies by Garza-Trevino et al 36 and Bieniek et al 44 concluded that the combination of haloperidol (5 mg) and lorazepam (4 mg and 2 mg, respectively) was statistically superior in producing more rapid tranquilization then either component medication alone. However, these studies do not use equipotent doses of the single drug when compared to the combination, so definite conclusions await further trials.
Conventional Antipsychotics
Haloperidol has by far the best evidence base among conventional antipsychotics for the treatment of agitation that may not extrapolate directly to the undifferentiated combative ED patient. Furthermore, studies comparing medications did not necessarily use equipotent dosages.
In a case series of general ED patients needing sedation, the safety and effectiveness of haloperidol alone was demonstrated by Clinton et al. 45 The authors treated 136 agitated patients with haloperidol (average dose 8.4 mg) and found that behavior was alleviated in 113 patients with only 3 patients showing no response. Four complications were noted, including 2 cases of dystonia.
Haloperidol compared with benzodiazepines was considered previously. Several studies found little to no additional benefit in sedation after 10 mg of IM haloperidol had been administered to psychotic patients. 35, 37, 46 Droperidol is a butyrophenone structurally related to haloperidol but available only by injection and used primarily in anesthesia for postoperative nausea. Anecdotally, it has received strong support as a calming agent in behavioral emergencies. It was superior to haloperidol in acutely reducing the level of agitation in patients already physically restrained for violent behavior in a class II study comparing IM haloperidol 5 mg to IM droperidol 5 mg.
47 Agitated patients receiving droperidol (5 mg) required fewer repeat doses than those receiving an equivalent dose of haloperidol. 48 Richards et al, 49 a class II study, is the largest prospective, randomized study of undifferentiated agitation using droperidol in an ED setting. The authors compared weight-based doses of IV droperidol to IV lorazepam. Sedation was similar at 5 minutes in the 2 groups, but thereafter, droperidol was significantly better in producing sedation up through 60 minutes. The study showed that patients treated with intravenous droperidol had lower sedation scores, required fewer repeat doses, and had shorter ED lengths of stay. One case of dystonia was reported.
In 2001, the US Food and Drug Administration (FDA) issued a black box warning about droperidol's potential for dysrhythmias, making its subsequent use problematic. However, large patient series have appeared attesting to its safety. Chase and Biros 50 reviewed their use of droperidol in 2,468 ED patients, with 1,357 receiving it for agitation. Few (6) adverse events occurred, none in patients without serious comorbidities, and none were documented dysrhythmias. No dysrhythmic events were observed in an estimated 12,000 patients treated with droperidol for violence and/or agitation. 51 Some authors have reviewed the existing reports of droperidol toxicity, including all of the material submitted to the FDA on which the ruling was based, and concluded that although droperidol can be associated with prolongation of the QT interval, there is not convincing evidence that the drug causes severe cardiac events.
52,53

Atypical Antipsychotics
Atypical antipsychotics are noted for their differing mechanism of action, lower rates of motor side effects, and their efficacy in long-term treatment. 32, 54 Harrigan et al, 55 in an open-label prospective class II randominized study, compared 4 atypical antipsychotics: olanzapine, ziprasidone, quetiapine, and risperidone with haloperidol and thioridazine. They concluded that all of the 6 antipsychotics studied, at their maximum recommended daily dosage, prolong the QTc interval at the steady-state peak plasma concentration. None, however, exceeded 500 ms. Thioridazine had the greatest QTc change and olanzapine the least.
Two class II reports showed that ziprasidone IM 20 mg is effective in rapidly and substantially reducing the symptoms of acute agitation in patients with known psychotic disorders, and it is well tolerated.
56,57 The efficacy of the 10-mg dose is not as great as the 20-mg dose, although it is significantly better than a 2-mg dose. The absence of movement disorders, including extrapyramidal symptoms, dystonia, and hypertonia with ziprasidone 20 mg is noteworthy. 56 In a class III study, ziprasidone IM was significantly more effective in reducing the symptoms of acute psychosis than haloperidol IM when each was dosed every 4 to 6 hours as needed. Ziprasidone was better tolerated, particularly in the incidence of movement disorders. 58 In the single report available using atypical antipsychotics in the undifferentiated patients with agitation presenting to a psychiatric ED, Preval et al 59 found that ziprasidone 20 mg IM decreased agitation scores quickly and equally to conventional therapy (usually haloperidol with lorazepam) and significantly decreased the mean restraint time when compared to a group of historic controls.
Olanzapine IM was compared to haloperidol IM for treatment of acute agitation in schizophrenic patients in 2 class II studies and found to be equivalent in reducing agitation.
60,61
Wright et al 61 demonstrated that olanzapine decreased the agitated behavior more quickly, as measured at 15 to 45 minutes, although thereafter there was no significant difference in the 2 treatment groups. There was a greater incidence of acute dystonia in the haloperidol group (7%). Meehan et al, 62, 63 in randomized double-blinded fashion, compared IM olanzapine with IM lorazepam in agitated patients with bipolar mania and patients with dementia, respectively. Sedation was equivalent in the dementia patients among treatment groups. In patients with bipolar mania, there was significantly greater reduction in agitation scores shown with olanzapine (10 mg) over lorazepam (2 mg) at 2 hours but equivalent at 24 hours. Breier et al 60 reported that hypotension occurred in 8 of 185 (4.3%) olanzapine-treated patients and 0 of 40 haloperidol and 0 of 45 placebo-treated patients. There are no published reports of vital sign measurements with IM olanzapine, but an FDA Psychopharmacological Drugs Advisory Committee briefing document cites a prevalence of 11.9% for a 20 mm Hg drop in systolic blood pressure in clinical trial subjects. 64 Orthostatic vital signs are recommended if repeated administration of olanzapine is contemplated. Concomitant use of IM olanzapine with benzodiazepines has not been studied and is not recommended by the manufacturer.
Currier et al, 65 in a rater-blinded randomized class II trial, found that oral treatment with risperidone (2 mg) and lorazepam (2 mg) was comparable to IM haloperidol (5 mg) and lorazepam (2 mg) for short-term treatment of agitated psychosis in patients who accept oral medications. Both treatment groups showed similar improvement in agitation, with similar times to sedation. It is possible that the group receiving intramuscular haloperidol and lorazepam had more severe psychotic agitation.
Future Areas of Research: (1) comparison of parenteral midazolam to lorazepam for the control of acute agitation, (2) role of combination therapy when individual drugs are used in doses equivalent to the combination, and (3) the role of the atypical antipsychotics as parental or oral monotherapy or in combination with a benzodiazepine for rapid control of the agitated ED patient. Retrospective observational analysis 345 patients with psychiatric complaints screened in an urban ED during a 2-mo period; 19% had an acute medical condition, the most common: lacerations, hyperglycemia, chest pain, hypertension, and bronchitis; history had 94% sensitivity for identifying these conditions; physical examination had 51% sensitivity for identifying the medical condition; vital signs 17% sensitivity; laboratory studies alone 20% sensitivity; self-reporting had 92% sensitivity; specificity was 91% for identifying those with positive drug screen result; 2 laboratory abnormalities were not detected by history and physical examination and both were low potassium levels: 2.9-3.1 mmol/L; history and physical examination picked up the vast majority of physical problems and substance abuse in the psychiatric patient 
